The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer.
 
Sarah Elizabeth Fenton
No Relationships to Disclose
 
Sheetal Mehta Kircher
Stock and Other Ownership Interests - Abbott/AbbVie; Penrose
 
Mary Frances Mulcahy
Research Funding - BTG
 
Devalingam Mahalingam
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Merck KGaA; Oncolytics
 
Riad Salem
Consulting or Advisory Role - AstraZeneca; Bard Medical; Boston Scientific; Cook Medical; Eisai; Genentech/Roche; QED Therapeutics; Sirtex Medical
Research Funding - BTG (Inst)
 
Robert Lewandowski
Consulting or Advisory Role - Abbisko; Bard Biopsy; Boston Scientific; Varian Biopharma
 
Laura Kulik
Honoraria - Eisai; Fujifilm; PeerView
Consulting or Advisory Role - Eisai; Exelixis; Genentech; Merck
Speakers' Bureau - Bayer/Onyx; Dova Pharmaceuticals; Gilead Sciences
Research Funding - HCC Target (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Al Bowen Benson
Consulting or Advisory Role - American Cancer Society; Array BioPharma; BioNest; Bristol-Myers Squibb; Cancer Expert Now; Decision Resources; Harborside Press; Health Advances; i3 Health; Imedex; Lynx Group; Merck Sharp & Dohme; Merck Sharp & Dohme; Precisca; PrECOG; Research to Practice; Shanghai International Colorectal Cancer Symposium; Springer; The Dedham Group; Total Health Conferencing
Research Funding - Advanced Accelerator Applications (Inst); American College of Radiology (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); ECOG-ACRIN (Inst); Elevar Therapeutics (Inst); Infinity Pharmaceuticals (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); PrECOG (Inst); Rafael Pharmaceuticals (Inst); st pharm (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Tyme Inc (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Association of Community Cancer Centers (ACCC); Bristol-Myers Squibb; CancerCare; Lynx Group; Merck Sharp & Dohme; MJH Healthcare Holdings, LLC; NCCN; North American Neuroendocrine Tumor Society; NPAF/PAF
 
Aparna Kalyan
Honoraria - Samumed
Consulting or Advisory Role - Bristol-Myers Squibb; BTG; Eisai; Exelixis; Ipsen
Speakers' Bureau - Exelixis
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis